Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
about
Imatinib for treating newly diagnosed chronic myeloid leukemia patientsImatinib for treating patients with chronic myelogeneous leukemiaAnalysis of kinase gene expression patterns across 5681 human tissue samples reveals functional genomic taxonomy of the kinomeA gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses.Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies.Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia.Hematopoietic Lineage Transcriptome Stability and Representation in PAXgene Collected Peripheral Blood Utilising SPIA Single-Stranded cDNA Probes for Microarray.Therapy of chronic myeloid leukemia: twilight of the imatinib era?Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms.Role of gene-expression profiling in chronic myeloid leukemia.Mechanisms of resistance to BCR-ABL kinase inhibitors.Pain management in the 21st century: utilization of pharmacogenomics and therapeutic drug monitoring.Array-based pharmacogenomics of molecular-targeted therapies in oncology.Advances in molecular diagnostics of myeloproliferative disorders.Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer.Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia.Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment.Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach
P2860
Q24186877-60B9C2C2-D904-4A24-AE2F-D189441F1E65Q24241730-9842C72C-696D-4BED-8B05-7C39759A9966Q28476427-54F24162-6364-470F-9455-9B65F9EFD565Q33597519-5641B843-AB64-46FB-AEB0-E549A8838447Q36280423-AEEAA4D7-FD0A-46E7-8D6F-062C8D0B8E34Q36412663-B6822C1B-96AD-495D-BCAF-793504F60933Q37132871-0ADD23A4-CEA5-422D-9AC0-5336EAC1C194Q37207320-A6945ABE-B640-4DC9-A726-6094BE55BD62Q37593435-790B63CD-24B4-4EA5-AA2F-CBF964F8FAB0Q37810110-4DDBB704-B8B9-4316-AC00-5ADBCEC2ABCFQ37810111-72A0DCDF-3CA4-4754-918B-0346ECB94DEAQ37836923-7FD6267B-59F6-4534-A931-195886F8DD7DQ37876422-1BB47EE4-8AC3-4714-BD3A-F02E853E4D38Q37976288-33D89923-CF4F-4CE3-B4D3-B41FD28EC670Q38089228-AB7BCD1A-CFED-4961-AEAC-FCA2127A0DEFQ39409196-AA525D17-F2A8-4E3A-ADCF-C2BC815502D2Q40321847-3C70B3FC-1FE1-4978-A51E-A766E01F5A7DQ46418288-FD4F406F-2667-41D5-A6BE-47DE0E469109Q46970334-B2EBF9CB-9B76-48CD-9223-9E6509621A55Q47440281-293CCC33-91EA-4A93-A45C-444843701340Q58010946-1C5ABC0B-64CE-4142-AF62-DF192C642511
P2860
Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pharmacogenomic analysis of cy ...... atients treated with imatinib.
@en
type
label
Pharmacogenomic analysis of cy ...... atients treated with imatinib.
@en
prefLabel
Pharmacogenomic analysis of cy ...... atients treated with imatinib.
@en
P2093
P921
P1476
Pharmacogenomic analysis of cy ...... atients treated with imatinib.
@en
P2093
Insa Gathmann
Lee Anne McLean
Marlene Dressman
Mihael H Polymeropoulos
Renaud Capdeville
P304
P356
10.1158/1078-0432.CCR-0784-3
P407
P433
P577
2004-01-01T00:00:00Z